Stockscreener 앱 받기
23.59
2.19%
-0.585
전일 마감가:
$24.18
열려 있는:
$24.5
하루 거래량:
135.12K
Relative Volume:
0.15
시가총액:
$1.39B
수익:
$13.05M
순이익/손실:
$-60.54M
주가수익비율:
-20.34
EPS:
-1.16
순현금흐름:
$-37.82M
1주 성능:
-1.52%
1개월 성능:
-1.29%
6개월 성능:
-39.93%
1년 성능:
-32.98%
1일 변동 폭
$23.46
$24.66
1주일 범위
$23.16
$26.50
52주 변동 폭
$22.48
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
명칭
Janux Therapeutics Inc
전화
(858) 751-4493
주소
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
JANX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
23.54 | 1.51B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.78 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.99 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.97 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.10 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
296.30 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-11 | 개시 | Raymond James | Outperform |
| 2024-12-03 | 재확인 | BTIG Research | Buy |
| 2024-12-03 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-22 | 개시 | Leerink Partners | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-05-30 | 개시 | Scotiabank | Sector Perform |
| 2024-03-21 | 개시 | BTIG Research | Buy |
| 2024-03-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 개시 | Wedbush | Outperform |
| 2022-11-14 | 개시 | William Blair | Outperform |
모두보기
Janux Therapeutics Inc 주식(JANX)의 최신 뉴스
Janux Therapeutics reaches clinical milestone in Merck TRACTr collaboration - TipRanks
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck - Yahoo Finance
Is Janux Therapeutics Inc. a growth stock or a value stockSuperior return velocity - Jammu Links News
What analysts say about Janux Therapeutics Inc. stockTrack top-performing stocks in real-time - Jammu Links News
What are the latest earnings results for Janux Therapeutics Inc.Build wealth faster with consistent investment plans - Jammu Links News
Should I hold or sell Janux Therapeutics Inc. stock in 2025Free Market Dynamics Reports - Jammu Links News
What drives Janux Therapeutics Inc. stock priceExplosive trading growth - Jammu Links News
Janux Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough gains with expert advice - Jammu Links News
How does Janux Therapeutics Inc. generate profit in a changing economyMaximize your gains with professional insights - Jammu Links News
Is Janux Therapeutics Inc. stock overvalued or undervaluedMaximize gains with data-driven stock picks - Jammu Links News
What makes Janux Therapeutics Inc. stock price move sharplyAccess powerful market insights for free - Jammu Links News
What are analysts’ price targets for Janux Therapeutics Inc. in the next 12 monthsUnlock your portfolio’s hidden potential - Jammu Links News
How does Janux Therapeutics Inc. compare to its industry peersAccelerated financial growth - Jammu Links News
Can Janux Therapeutics Inc. Regain Momentum After BreakdownReal Trader Watchlist of Hot Stocks Released - metal.it
Optimistic Buy Rating for Janux Therapeutics Driven by Strategic Pipeline and Diversification - TipRanks
Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash - Seeking Alpha
Why Janux Therapeutics Inc. stock attracts strong analyst attentionTriple Return Setup With Risk Control Explained - metal.it
Janux Therapeutics Receives Buy Rating from Leerink Partners Analyst Jeffrey La Rosa - AInvest
Why did JANX's operating expenses surge in Q3 2024? - AInvest
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Praise Ionis Pharmaceuticals and Janux Therapeutics for Bright Healthcare Futures - AInvest
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $90 - 富途牛牛
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Combining machine learning predictions for Janux Therapeutics Inc. Yield Curve Outlook and Long-Term Implication Summary - metal.it
What is the dividend policy of Janux Therapeutics Inc. stockSuperior stock selection - Jammu Links News
Evercore ISI Analyst Maintains Buy Rating on Janux Therapeutics with $25.00 Price Target - AInvest
Janux Therapeutics Inc: Strategic Advancements and Strong Positioning in Oncology Drive Buy Rating - TipRanks
Adc Therapeutics Sa shares fall 1.83% after-hours following Janux Therapeutics' R&D Day press release. - AInvest
Why Intel Stock Is Plummeting Today - The Globe and Mail
What makes Janux Therapeutics Inc. stock attractive to long term investorsRapid-fire capital growth - Jammu Links News
Janux Therapeutics’ Strategic Expansion and Promising Pipeline Drive Buy Rating - TipRanks
Janux Therapeutics' Innovative Preclinical Programs and Strategic Tumor Activation Drive Buy Rating - AInvest
Janux Therapeutics Faces Trade Policy Challenges: Impact on Operations and Growth - TipRanks
Innovative Preclinical Programs and Strategic Tumor Activation Drive Buy Rating for Janux Therapeutics - TipRanks
Is Janux Therapeutics Inc. stock a growth or value playHigh-profit capital plays - Jammu Links News
Janux Therapeutics Inc (JANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.28%
2.25%
자본화:
|
볼륨(24시간):